zanamivir 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antivirals neuraminidase inhibitors 2859 139110-80-8

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • zanamivir
  • relenza
  • zanamivir hydrate
A guanido-neuraminic acid that is used to inhibit NEURAMINIDASE.
  • Molecular weight: 332.31
  • Formula: C12H20N4O7
  • CLOGP: -5.56
  • LIPINSKI: 2
  • HAC: 11
  • HDO: 8
  • TPSA: 198.22
  • ALOGS: -2.35
  • ROTB: 6
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
20 mg Inhal.powder
1.20 g P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 18 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 100 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.86 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 2 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.23 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 1.60 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.86 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 1.70 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
April 26, 2019 EMA GlaxoSmithKline Trading Services Limited
July 26, 1999 FDA GLAXOSMITHKLINE

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Exposure during pregnancy 591.07 38.83 204 1642 136138 56154083
Abnormal behaviour 379.52 38.83 95 1751 20177 56270044
Delivery 192.34 38.83 32 1814 857 56289364
Hallucination 120.54 38.83 49 1797 49100 56241121
Overdose 118.24 38.83 61 1785 105769 56184452
Loss of consciousness 70.35 38.83 44 1802 109305 56180916
Delirium 69.92 38.83 32 1814 42485 56247736
No adverse event 58.60 38.83 27 1819 36347 56253874
Altered state of consciousness 46.39 38.83 20 1826 23001 56267220

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Abnormal behaviour 1085.43 46.08 255 1651 23573 31671865
Hallucination 216.93 46.08 87 1819 46323 31649115
Delirium 137.50 46.08 61 1845 41360 31654078
Overdose 125.03 46.08 72 1834 84592 31610846
Aggression 86.69 46.08 43 1863 37248 31658190
Screaming 84.68 46.08 19 1887 1342 31694096
Restlessness 63.46 46.08 30 1876 23331 31672107
Amnesia 63.41 46.08 30 1876 23372 31672066
Hallucination, auditory 50.10 46.08 20 1886 10340 31685098
Loss of consciousness 46.76 46.08 38 1868 77317 31618121
Depressed level of consciousness 46.74 46.08 29 1877 38572 31656866
Crying 46.19 46.08 16 1890 5581 31689857

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Abnormal behaviour 1007.32 37.61 236 2380 34473 70891355
Overdose 304.78 37.61 140 2476 169605 70756223
Hallucination 250.97 37.61 97 2519 76163 70849665
No adverse event 146.28 37.61 52 2564 32101 70893727
Delirium 128.31 37.61 60 2556 74554 70851274
Exposure via breast milk 107.98 37.61 20 2596 887 70924941
Exposure during pregnancy 87.81 37.61 49 2567 87668 70838160
Screaming 70.21 37.61 18 2598 3654 70922174
Loss of consciousness 55.76 37.61 46 2570 155670 70770158
Pathogen resistance 54.75 37.61 20 2596 13259 70912569
Restlessness 51.77 37.61 27 2589 42101 70883727
Aggression 48.23 37.61 27 2589 48419 70877409
Hallucination, auditory 41.81 37.61 18 2598 18310 70907518
Altered state of consciousness 38.99 37.61 22 2594 40000 70885828
Depressed level of consciousness 38.05 37.61 29 2587 87402 70838426

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC J05AH01 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIVIRALS FOR SYSTEMIC USE
DIRECT ACTING ANTIVIRALS
Neuraminidase inhibitors
FDA MoA N0000175436 Neuraminidase Inhibitors
FDA EPC N0000175524 Neuraminidase Inhibitor
CHEBI has role CHEBI:22587 antiviral agents
CHEBI has role CHEBI:52425 acetylneuraminidase inhibitors
MeSH PA D000890 Anti-Infective Agents
MeSH PA D000998 Antiviral Agents
MeSH PA D004791 Enzyme Inhibitors

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Influenza indication 6142004 DOID:8469
Delirium contraindication 2776000
Bronchospasm contraindication 4386001
Hallucinations contraindication 7011001
Chronic obstructive lung disease contraindication 13645005 DOID:3083
Feeling agitated contraindication 24199005
Seizure disorder contraindication 128613002
Impaired cognition contraindication 386806002




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 2.46 acidic
pKa2 12.0 acidic
pKa3 13.81 acidic
pKa4 13.85 acidic
pKa5 9.82 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Sialidase 3 Enzyme IC50 5.17 CHEMBL
Sialidase 2 Enzyme Ki 4.77 CHEMBL
Sialidase-4 Enzyme Ki 4.58 CHEMBL
Neuraminidase Enzyme INHIBITOR IC50 9.30 CHEMBL CHEMBL
Neuraminidase Enzyme INHIBITOR Ki 10 CHEMBL CHEMBL
Neuraminidase Enzyme IC50 8.58 CHEMBL
Neuraminidase Enzyme Ki 9.30 CHEMBL
Neuraminidase Enzyme Ki 9 CHEMBL
Neuraminidase Enzyme Ki 9.40 CHEMBL
Neuraminidase Enzyme Ki 9.30 CHEMBL
Neuraminidase Enzyme IC50 7.64 CHEMBL
Neuraminidase Enzyme IC50 8.54 CHEMBL
Neuraminidase Enzyme IC50 5.85 CHEMBL
Neuraminidase Enzyme IC50 8.13 CHEMBL
Neuraminidase Enzyme IC50 8.05 CHEMBL
Neuraminidase Enzyme IC50 8.47 CHEMBL
Neuraminidase Enzyme IC50 8.76 CHEMBL
Neuraminidase Enzyme IC50 7.64 CHEMBL
Neuraminidase Enzyme IC50 8.40 WOMBAT-PK
Neuraminidase Enzyme Kd 8.33 CHEMBL
Neuraminidase Enzyme IC50 8.62 CHEMBL

External reference:

IDSource
4021167 VUID
N0000148618 NUI
D00902 KEGG_DRUG
4021167 VANDF
C0216660 UMLSCUI
CHEBI:50663 CHEBI
ZMR PDB_CHEM_ID
CHEMBL222813 ChEMBL_ID
CHEMBL1673195 ChEMBL_ID
DB00558 DRUGBANK_ID
D053243 MESH_DESCRIPTOR_UI
60855 PUBCHEM_CID
7272 INN_ID
551942-41-7 SECONDARY_CAS_RN
L6O3XI777I UNII
261633 RXNORM
31156 MMSL
8261 MMSL
d04443 MMSL
007857 NDDF
116100000 SNOMEDCT_US
1217563005 SNOMEDCT_US
387010007 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
RELENZA HUMAN PRESCRIPTION DRUG LABEL 1 0173-0681 POWDER 5 mg RESPIRATORY (INHALATION) NDA 26 sections
RELENZA HUMAN PRESCRIPTION DRUG LABEL 1 0173-0681 POWDER 5 mg RESPIRATORY (INHALATION) NDA 26 sections
RELENZA HUMAN PRESCRIPTION DRUG LABEL 1 54868-4377 POWDER 5 mg RESPIRATORY (INHALATION) NDA 25 sections
RELENZA HUMAN PRESCRIPTION DRUG LABEL 1 68258-3030 POWDER 5 mg RESPIRATORY (INHALATION) NDA 25 sections